Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
8.87
-0.03 (-0.34%)
At close: Nov 7, 2025, 4:00 PM EST
8.72
-0.15 (-1.69%)
After-hours: Nov 7, 2025, 7:33 PM EST
Amicus Therapeutics Revenue
Amicus Therapeutics had revenue of $169.06M in the quarter ending September 30, 2025, with 19.46% growth. This brings the company's revenue in the last twelve months to $598.70M, up 21.28% year-over-year. In the year 2024, Amicus Therapeutics had annual revenue of $528.30M with 32.29% growth.
Revenue (ttm)
$598.70M
Revenue Growth
+21.28%
P/S Ratio
4.56
Revenue / Employee
$1,199,808
Employees
499
Market Cap
2.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 528.30M | 128.94M | 32.29% |
| Dec 31, 2023 | 399.36M | 70.12M | 21.30% |
| Dec 31, 2022 | 329.23M | 23.72M | 7.76% |
| Dec 31, 2021 | 305.51M | 44.63M | 17.11% |
| Dec 31, 2020 | 260.89M | 78.65M | 43.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
FOLD News
- 3 days ago - Amicus Therapeutics, Inc. (FOLD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates - GlobeNewsWire
- 8 days ago - Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025 - GlobeNewsWire
- 16 days ago - Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025 - GlobeNewsWire
- 16 days ago - Amicus Therapeutics: Turning The Corner To Profitability With 2 Developing Therapies - Seeking Alpha
- 5 weeks ago - 3 Of My Favorite Biotech Stocks Under $10 - Seeking Alpha
- 2 months ago - Amicus Therapeutics, Inc. (FOLD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 2 months ago - New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM - GlobeNewsWire